---
id: antimicrobial-stewardship_119
category: stewardship
tags: [antimicrobial-stewardship, ASP, antibiotic-resistance, CDC-core-elements, stewardship-interventions]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Antimicrobial Stewardship Principles

**Q:** What are the core elements of antimicrobial stewardship programs (ASP), key interventions, metrics for success, and strategies to combat antibiotic resistance?

**A:**

## OVERVIEW

**Antimicrobial Stewardship:** Coordinated interventions designed to improve and measure the appropriate use of antimicrobials by promoting:
- **Selection of optimal drug, dose, duration, and route**
- **Prevention of antimicrobial resistance**
- **Improved patient outcomes**
- **Reduced adverse events** (C. difficile, resistance)

**Key Point:** **ASP = right drug, right dose, right duration, right patient**

---

## CDC CORE ELEMENTS OF HOSPITAL ANTIBIOTIC STEWARDSHIP PROGRAMS

**Mnemonic: "LATTE" (Leadership, Action, Tracking, Training, Education)**

### **1. LEADERSHIP COMMITMENT**
- **Dedicate resources** (personnel, financial support)
- **Accountability** (single leader responsible for program outcomes)

### **2. ACCOUNTABILITY**
- **Single leader** (ID physician or pharmacist) responsible for ASP
- **Co-leadership model** (physician + pharmacist)

### **3. DRUG EXPERTISE**
- **Pharmacy expertise** (clinical pharmacist with ID training)
- **Access to microbiology data** (antibiograms, susceptibility patterns)

### **4. ACTION**
- **Implement interventions:**
  - **Prospective audit and feedback** (PAF)
  - **Preauthorization/Formulary restriction**
  - **Clinical pathways/Guidelines**
  - **Dose optimization**

### **5. TRACKING**
- **Monitor antibiotic use** (DOT = days of therapy per 1000 patient-days)
- **Monitor resistance patterns** (institutional antibiogram)
- **Measure outcomes** (C. diff rates, resistance rates)

### **6. REPORTING**
- **Regular reports** to leadership, clinicians, infection control
- **Feedback on prescribing practices**

### **7. EDUCATION**
- **Clinician education** (prescribers, nurses, pharmacists)
- **Patient education** (appropriate antibiotic use)

**Key Point:** **CDC Core Elements = 7 components** (leadership, accountability, expertise, action, tracking, reporting, education)

---

## KEY STEWARDSHIP INTERVENTIONS

### **1. PROSPECTIVE AUDIT AND FEEDBACK (PAF)**

**Definition:** Review of antimicrobial prescriptions after initiation → provide feedback to prescribers

**Advantages:**
- **More acceptable to prescribers** (less restrictive than preauthorization)
- **Educational opportunity** (real-time teaching)
- **Flexibility** (allows prescriber autonomy)

**Timing:** **48-72 hours** after antibiotic initiation (allows time for culture results)

**Key Point:** **PAF = most commonly used stewardship strategy** (review → feedback)

---

### **2. PREAUTHORIZATION / FORMULARY RESTRICTION**

**Definition:** Require approval before prescribing specific "restricted" antibiotics

**Commonly Restricted Agents:**
- **Carbapenems** (meropenem, imipenem, ertapenem)
- **Anti-MRSA agents** (daptomycin, linezolid)
- **Antifungals** (voriconazole, posaconazole, echinocandins)
- **Broad-spectrum agents** (ceftazidime-avibactam, ceftolozane-tazobactam)

**Advantages:**
- **Immediate impact** on antibiotic use
- **Prevents inappropriate use**

**Disadvantages:**
- **Prescriber dissatisfaction** (perceived lack of autonomy)
- **Delays in therapy** (if not staffed 24/7)

**Key Point:** **Preauthorization = gatekeeper** (approval required before use)

---

### **3. CLINICAL PATHWAYS / GUIDELINES**

**Examples:**
- **Empiric therapy for community-acquired pneumonia** (CAP)
- **Antibiotic duration for common infections** (UTI, pneumonia)
- **De-escalation protocols** (broad → narrow spectrum based on cultures)

**Key Point:** **Standardized guidelines reduce practice variation**

---

### **4. DOSE OPTIMIZATION**

**Focus Areas:**
- **Renal dose adjustment** (prevent toxicity)
- **TDM (Therapeutic Drug Monitoring)** for vancomycin, aminoglycosides
- **Extended/Continuous infusions** (beta-lactams like piperacillin-tazobactam, meropenem)

**Key Point:** **PK/PD optimization** (maximize efficacy, minimize toxicity)

---

### **5. IV-TO-PO CONVERSION**

**Criteria:**
- **Hemodynamically stable**
- **Tolerating PO intake**
- **GI tract functional**
- **Bioavailable oral agent available**

**High Bioavailability Agents (Near 100%):**
- **Fluoroquinolones** (levofloxacin, moxifloxacin)
- **Linezolid**
- **Metronidazole**
- **Fluconazole**
- **TMP-SMX**

**Key Point:** **IV-to-PO switch reduces costs, line complications** (CLABSI)

---

### **6. DE-ESCALATION**

**Definition:** Narrow antimicrobial spectrum based on culture/susceptibility results

**Example:**
- **Empiric:** Vancomycin + piperacillin-tazobactam (for sepsis)
- **De-escalate:** Cefazolin (if MSSA identified on blood culture)

**Key Point:** **Start broad → narrow based on cultures** (de-escalation reduces resistance)

---

### **7. ANTIBIOTIC TIME-OUTS**

**Definition:** Reassess antibiotic therapy at **48-72 hours** after initiation

**Key Questions:**
1. **Does the patient have an infection?** (vs colonization, non-infectious cause)
2. **Are antibiotics still indicated?**
3. **Can we de-escalate** based on cultures?
4. **What is the appropriate duration?**

**Key Point:** **Time-out at 48-72 hours** → reassess necessity, de-escalate, determine duration

---

## METRICS FOR STEWARDSHIP SUCCESS

### **Process Measures:**

| **Metric** | **Definition** | **Target** |
|------------|----------------|------------|
| **DOT** (Days of Therapy) | **Days of antibiotic use per 1000 patient-days** | Decrease over time |
| **LOT** (Length of Therapy) | **Days patient receives ≥1 antibiotic per 1000 patient-days** | Decrease over time |
| **DDD** (Defined Daily Dose) | WHO-standardized metric | Decrease over time |

### **Outcome Measures:**

| **Metric** | **Target** |
|------------|------------|
| **C. difficile infection rate** | **Decrease** (per 10,000 patient-days) |
| **Antimicrobial resistance rates** | Stable or decrease (e.g., MRSA, CRE) |
| **Readmission rates** | No increase (ensure quality maintained) |
| **Mortality** | No increase |

**Key Point:** **DOT = most commonly used metric** (days of therapy per 1000 patient-days)

---

## APPROPRIATE ANTIBIOTIC DURATION

**Shorter Durations are Non-Inferior for Many Infections:**

| **Infection** | **Traditional Duration** | **Evidence-Based Shorter Duration** |
|---------------|--------------------------|-------------------------------------|
| **Community-Acquired Pneumonia (CAP)** | 7-10 days | **5 days** (if afebrile x 48-72 hours, clinically stable) |
| **Hospital-Acquired Pneumonia (HAP)** | 14-21 days | **7 days** (if good clinical response) |
| **Uncomplicated UTI (cystitis)** | 7 days | **3 days** (TMP-SMX or fluoroquinolone) |
| **Pyelonephritis** | 14 days | **7 days** (fluoroquinolone) |
| **Skin/Soft Tissue Infection (cellulitis)** | 10-14 days | **5-6 days** (if improving) |
| **Intra-Abdominal Infection (source controlled)** | 7-10 days | **4 days** (if source control achieved) |

**Key Point:** **Shorter durations = less resistance, fewer adverse events** (C. diff, yeast superinfection)

---

## STRATEGIES TO COMBAT ANTIBIOTIC RESISTANCE

**Key Drivers of Resistance:**
1. **Overuse of antibiotics** (unnecessary prescriptions)
2. **Prolonged durations** (beyond evidence-based recommendations)
3. **Broad-spectrum use** (carbapenem, fluoroquinolone overuse)

**Stewardship Strategies:**
- **Avoid antibiotics for viral infections** (URI, bronchitis)
- **Use narrow-spectrum agents** when possible (e.g., cefazolin for MSSA)
- **Shorten durations** (based on clinical response)
- **De-escalate therapy** (based on cultures)
- **Cyclic use of antibiotics** (rotate antibiotic classes to reduce selective pressure)

**Key Point:** **Judicious use of antibiotics reduces resistance** (narrow spectrum, shorter duration)

---

## STEWARDSHIP IN SPECIFIC SCENARIOS

### **1. ASYMPTOMATIC BACTERIURIA (ASB)**

**Definition:** Bacteria in urine **without symptoms** (pyuria alone is NOT sufficient)

**Do NOT Treat EXCEPT:**
- **Pregnancy**
- **Before urologic surgery** (with mucosal trauma)

**Key Point:** **ASB = no treatment** (except pregnancy, urologic surgery)

---

### **2. POSITIVE URINE CULTURE WITH CATHETER**

**Common Scenario:** Urine culture ordered for non-specific symptoms (fever, delirium)

**Approach:**
- **Is catheter present?** If yes, ASB is common (do NOT treat unless symptoms)
- **Remove catheter** if no longer needed

**Key Point:** **Catheter + positive culture ≠ CAUTI** (need symptoms)

---

### **3. PROCALCITONIN-GUIDED THERAPY**

**Use:** Guide antibiotic discontinuation in respiratory infections (CAP, COPD exacerbation)

**Strategy:**
- **Low procalcitonin (<0.25 ng/mL)** → consider stopping antibiotics (bacterial infection unlikely)
- **High procalcitonin (>0.5 ng/mL)** → bacterial infection likely (continue antibiotics)

**Key Point:** **Procalcitonin <0.25 ng/mL** → consider stopping antibiotics (reduces antibiotic duration)

---

## ANTIMICROBIAL STEWARDSHIP TARGETS (HIGH-YIELD)

**"High-Value Targets" for Stewardship Interventions:**

1. **Vancomycin**
   - **Overused for:** CoNS (often contaminant), empiric MRSA coverage (when low risk)
   - **Action:** Discontinue if cultures negative at 48-72 hours

2. **Fluoroquinolones**
   - **Associated with:** C. diff, tendon rupture, QT prolongation, resistance
   - **Action:** Restrict use, prefer narrow-spectrum alternatives

3. **Carbapenems**
   - **Overused for:** ESBL organisms (can often use alternatives like ceftolozane-tazobactam, ceftazidime-avibactam)
   - **Action:** Carbapenem-sparing strategies (protect "last-line" agents)

4. **3rd-Generation Cephalosporins**
   - **Associated with:** ESBL selection, C. diff
   - **Action:** Prefer 1st-generation cephalosporins if susceptible (e.g., cefazolin for MSSA)

5. **Azithromycin**
   - **Overused for:** Non-bacterial infections (bronchitis)
   - **Action:** Restrict to evidence-based indications (CAP, atypical coverage)

**Key Point:** **Target high-risk antibiotics** (vancomycin, fluoroquinolones, carbapenems)

---

**Clinical Pearls:**
- **CDC Core Elements = 7 components** (leadership, accountability, expertise, action, tracking, reporting, education)
- **PAF = most common intervention** (prospective audit and feedback at 48-72 hours)
- **Antibiotic time-out at 48-72 hours** (reassess necessity, de-escalate, determine duration)
- **DOT = days of therapy per 1000 patient-days** (primary metric)
- **Shorter durations = non-inferior** (CAP 5 days, HAP 7 days, cellulitis 5-6 days)
- **Do NOT treat asymptomatic bacteriuria** (except pregnancy, urologic surgery)
- **Target high-risk antibiotics:** Vancomycin, fluoroquinolones, carbapenems
- **De-escalation = broad → narrow** (based on cultures)
- **IV-to-PO switch reduces CLABSI risk** (fluoroquinolones, linezolid, fluconazole = high bioavailability)

**Media:** None

**Sources:** [CDC 2024 - Core elements of hospital ASP], [IDSA/SHEA 2016 - Implementing an ASP], [IDSA 2024 - AMR guidance]
